FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says
Executive Summary
The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn
You may also be interested in...
Pfizer’s Lyrica: “Approvable” For Three Indications, Not Generalized Anxiety
Pfizer's Lyrica (pregabalin) is "approvable" for three of four requested indications
Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”
Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17
Pfizer, PhRMA See Signs Of Drug Approval "Slowdown" At FDA
Pfizer believes that several of its pending products have been delayed by an "across-the-board" slowdown in FDA approvals, CEO Henry McKinnell told investors during the company's Jan. 24 quarterly conference call.